Unknown

Dataset Information

0

Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety.


ABSTRACT: This phase II trial evaluated clinical markers of efficacy and safety of exemestane in postmenopausal women at increased risk for breast cancer. Postmenopausal women (n = 42) at risk for invasive breast cancer received 25 mg exemestane daily for 2 years along with calcium and vitamin D. The primary outcome was change in mammographic density (MD) after one year. Secondary outcomes included change in serum steroid hormones as well as change in trefoil protein 1 (TFF1) and proliferating cell nuclear antigen (PCNA) in breast tissue. Safety and tolerability were also assessed. MD decreased at 1 year and was significant at 2 years [mean change = -4.1%; 95% confidence intervals (CI), -7.2 to -1.1; P = 0.009]. Serum estradiol and testosterone levels significantly decreased at 3 months and remained suppressed at 12 months. After 1 year of treatment, TFF1 intensity decreased (mean change -1.32; 95% CI, -1.87 to -0.76; P < 0.001). Exemestane was safe and well tolerated. Exemestane decreased MD and expression of breast tissue TFF1. It was well tolerated with few clinically relevant side effects. MD and breast tissue TFF1 are potential biomarkers of breast cancer-preventive effects of exemestane in high-risk postmenopausal women.

SUBMITTER: Gatti-Mays ME 

PROVIDER: S-EPMC4777638 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety.

Gatti-Mays Margaret E ME   Venzon David D   Galbo Claudia E CE   Singer Andrea A   Reynolds James J   Makariou Erini E   Kallakury Bhaskar B   Heckman-Stoddard Brandy M BM   Korde Larissa L   Isaacs Claudine C   Warren Robert R   Gallagher Ann A   Eng-Wong Jennifer J  

Cancer prevention research (Philadelphia, Pa.) 20160112 3


This phase II trial evaluated clinical markers of efficacy and safety of exemestane in postmenopausal women at increased risk for breast cancer. Postmenopausal women (n = 42) at risk for invasive breast cancer received 25 mg exemestane daily for 2 years along with calcium and vitamin D. The primary outcome was change in mammographic density (MD) after one year. Secondary outcomes included change in serum steroid hormones as well as change in trefoil protein 1 (TFF1) and proliferating cell nuclea  ...[more]

Similar Datasets

| S-EPMC3201097 | biostudies-other
| S-EPMC2747391 | biostudies-other
| S-EPMC8429140 | biostudies-literature
| S-EPMC3612593 | biostudies-literature
| S-EPMC3616612 | biostudies-literature
| S-EPMC6587781 | biostudies-literature
| S-EPMC4807132 | biostudies-literature
2011-06-17 | GSE30010 | GEO
| S-EPMC5429096 | biostudies-literature
| S-EPMC8080120 | biostudies-literature